TJ Cradick

Company: Gene Editing Frontiers

Job title: Chief Technology Officer

Seminars:

Exploring How Novel Nucleases & Appropriate Animal Models Are Key to Clinical Success 5:00 pm

Understand how engineering nucleases to improve on target efficacy and decrease off target effects was crucial to speeding up pre-clinical progression Evaluate how selecting mouse models and NHPs provide appropriate models to showcase efficacy and safety Reflect on how close collaboration between R&D and pre-clinic, as well as matching gene editing technology to appropriate indications,…Read more

day: Day Two

The Future: How Baby KJ’s Personalized CRISPR Therapy Will Facilitate Better Rare Disease Targeting 9:35 am

Following the groundbreaking work to launch the world’s first personalized CRISPR therapy to treat baby KJ, a new blueprint for rare disease treatment is forming. With the baby KJ team swiftly adapting base editing technology, rapidly co-ordinating regulatory approval and redefining clinical strategies, this session offers an unmissable insight into how this pioneering approach to…Read more

day: Pre-Conference Workshop Day